These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36161830)

  • 81. Final Outcomes from the Randomized RECOVERY Trial of Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy.
    Wykoff CC; Nittala MG; Villanueva Boone C; Yu HJ; Fan W; Velaga SB; Ehlers JP; Ip MS; Sadda SR;
    Ophthalmol Retina; 2022 Jul; 6(7):557-566. PubMed ID: 35257962
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab or triamcinolone.
    Prager SG; Lammer J; Mitsch C; Hafner J; Pemp B; Scholda C; Kundi M; Schmidt-Erfurth U; Kriechbaum K
    Acta Ophthalmol; 2018 Mar; 96(2):e195-e200. PubMed ID: 29063703
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes.
    Laugesen CS; Ostri C; Brynskov T; Lund-Andersen H; Larsen M; Vorum H; Sørensen TL
    Acta Ophthalmol; 2017 Feb; 95(1):28-32. PubMed ID: 27473397
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Comparison of aflibercept and ranibizumab in diabetic macular edema associated with subretinal detachment.
    Ozkaya A; Demir G; Kirmaci A
    Eur J Ophthalmol; 2020 Mar; 30(2):363-369. PubMed ID: 30757913
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
    Spooner K; Fraser-Bell S; Hong T; Chang A
    Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment.
    Do DV; Nguyen QD; Khwaja AA; Channa R; Sepah YJ; Sophie R; Hafiz G; Campochiaro PA;
    JAMA Ophthalmol; 2013 Feb; 131(2):139-45. PubMed ID: 23544200
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Ranibizumab 0.3 mg for Persistent Diabetic Macular Edema After Recent, Frequent, and Chronic Bevacizumab: The ROTATE Trial.
    Fechter C; Frazier H; Marcus WB; Farooq A; Singh H; Marcus DM
    Ophthalmic Surg Lasers Imaging Retina; 2016 Nov; 47(11):1-18. PubMed ID: 27842191
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial.
    Mitchell P; Bressler N; Tolley K; Gallagher M; Petrillo J; Ferreira A; Wood R; Bandello F;
    JAMA Ophthalmol; 2013 Oct; 131(10):1339-47. PubMed ID: 23974915
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B).
    Hattenbach LO; Feltgen N; Bertelmann T; Schmitz-Valckenberg S; Berk H; Eter N; Lang GE; Rehak M; Taylor SR; Wolf A; Weiss C; Paulus EM; Pielen A; Hoerauf H;
    Acta Ophthalmol; 2018 Feb; 96(1):e10-e18. PubMed ID: 28251811
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Intravitreal Aflibercept versus Ranibizumab for Diabetic Macular Edema in a Taiwanese Health Service Setting.
    Tsai MJ; Cheng CK
    Semin Ophthalmol; 2021 Apr; 36(3):132-138. PubMed ID: 33661709
    [No Abstract]   [Full Text] [Related]  

  • 91. Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Clinical Practice of Single Center: Three-Year Outcomes.
    Choovuthayakorn J; Phinyo P; Tantraworasin A; Kunavisarut P; Patikulsila D; Chaikitmongkol V; Watanachai N; Pathanapitoon K
    Ophthalmic Res; 2021; 64(3):483-493. PubMed ID: 33053556
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial.
    Glassman AR; Baker CW; Beaulieu WT; Bressler NM; Punjabi OS; Stockdale CR; Wykoff CC; Jampol LM; Sun JK;
    JAMA Ophthalmol; 2020 Apr; 138(4):341-349. PubMed ID: 32077907
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors.
    Chatzirallis A; Theodossiadis P; Droutsas K; Koutsandrea C; Ladas I; Moschos MM
    Cutan Ocul Toxicol; 2020 Dec; 39(4):317-322. PubMed ID: 32722955
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Efficacy/safety of ranibizumab monotherapy or with laser versus laser monotherapy in DME.
    Berger A; Sheidow T; Cruess AF; Arbour JD; Courseau AS; de Takacsy F
    Can J Ophthalmol; 2015 Jun; 50(3):209-16. PubMed ID: 26040221
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Efficacy and safety of intravitreal injection of conbercept for moderate to severe nonproliferative diabetic retinopathy.
    Shen L; Zheng Y; Gao Z; Li Q; Dai M; Yang W; Zhang Q; Li D; Hu Y; Yuan L
    Front Med (Lausanne); 2024; 11():1394358. PubMed ID: 38846145
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Association of Predominantly Peripheral Lesions on Ultra-Widefield Imaging and the Risk of Diabetic Retinopathy Worsening Over Time.
    Marcus DM; Silva PS; Liu D; Aiello LP; Antoszyk A; Elman M; Friedman S; Glassman AR; Googe JM; Jampol LM; Martin DF; Melia M; Preston CM; Wykoff CC; Sun JK;
    JAMA Ophthalmol; 2022 Oct; 140(10):946-954. PubMed ID: 35980608
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Panretinal photocoagulation plus intravitreal conbercept for diabetic retinopathy in real world: a retrospective study.
    Wang X; Yao J; Li S; Zhang W; Wang L; Zhou A
    BMC Ophthalmol; 2023 Oct; 23(1):400. PubMed ID: 37794367
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Diabetic Population-Based Model to Estimate Impact of Ranibizumab on Diabetic Retinopathy Severity in Patients with Diabetic Macular Edema.
    Varma R; Bressler NM; Doan QV; Suñer IJ; Danese M; Dolan CM; Lee A; Ehrlich JS; Rajput Y
    Clin Ophthalmol; 2020; 14():1249-1259. PubMed ID: 32440092
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Proliferative Diabetic Retinopathy Events in Patients With Diabetic Macular Edema: Post Hoc Analysis of VISTA and VIVID Trials.
    Do DV; Gordon C; Suñer IJ; Reed K; Moini H; Gibson A; Du W; Shah CP
    J Vitreoretin Dis; 2022; 6(4):295-301. PubMed ID: 37007930
    [TBL] [Abstract][Full Text] [Related]  

  • 100. ROBIN: a randomised, double-masked, placebo-controlled Phase IIa study of the AOC3 inhibitor BI 1467335 in diabetic retinopathy.
    Dong Nguyen Q; Ehlers JP; Boyer DS; Jin X; Giani A; Ehrlich MS;
    Eye (Lond); 2024 Jul; 38(10):1861-1869. PubMed ID: 38806700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.